Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1996 • 1,908 citations

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

2000 • 1,536 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.

1997 • 525 citations

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

2002 • 494 citations

A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

2004 • 479 citations

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients

1997 • 288 citations

Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.

1996 • 246 citations

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

2002 • 241 citations

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

2003 • 212 citations

A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy

2005 • 173 citations

Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas

2000 • 130 citations

Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

2005 • 107 citations

Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.

2001 • 101 citations

Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy

2005 • 98 citations

Circulating Vascular Endothelial Growth Factor in Patients With Colorectal Cancer

1998 • 94 citations

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

2004 • 92 citations

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy

2005 • 83 citations

Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma

2002 • 75 citations

Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells

1998 • 69 citations

Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.

1990 • 52 citations

Chemotherapy and Angiogenesis in Advanced Cancer: Vascular Endothelial Growth Factor (VEGF) Decline as Predictor of Disease Control during Taxol Therapy in Metastatic Breast Cancer

2000 • 46 citations

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

2005 • 42 citations

Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation

2004 • 28 citations

S7 Combination cyclophosphamide — UFT metronomic low-dose chemotherapy for the treatment of metastatic breast cancer: A preclinical analysis

2005 • 14 citations

SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE IN PEDIATRIC MALIGNANCIES

2005 • 9 citations